{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:44:21Z","timestamp":1759333461256},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":9065,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1987,10]]},"abstract":"<jats:p>A 10\u2010year old female on phenytoin therapy developed a rash and lymphadenopathy. H.p.l.c. assays of urinary metabolites indicated no differences in stereoselective metabolism of phenytoin to phenolic and dihydrodiol metabolites as compared with volunteers given the drug or with pediatric patients without adverse reactions. This suggests that no obvious difference in stereoselective metabolism of phenytoin to potentially toxic arene oxides exists between this patient and other patients on phenytoin. Our results are consistent with the hypothesis that differences in peripheral detoxication of phenytoin arene oxides and not differences in hepatic metabolism of phenytoin may be responsible for such adverse reactions.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1987.tb03212.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T23:31:49Z","timestamp":1343345509000},"page":"554-557","source":"Crossref","is-referenced-by-count":4,"title":["Apparently normal phenytoin metabolism in a patient with phenytoin\u2010 induced rash and lymphadenopathy."],"prefix":"10.1111","volume":"24","author":[{"given":"JH","family":"Maguire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Wettrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Rane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1977.tb04475.x"},{"key":"e_1_2_1_3_1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood.V61.5.889.889","article-title":"Anticonvulsant\u2010induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro","volume":"61","author":"Gerson W. T.","year":"1983","journal-title":"Blood"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.185.4151.573"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-197901030-00009"},{"key":"e_1_2_1_6_1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0378-4347(00)84523-5","article-title":"Urinary dihydrodiol metabolites of phenytoin: HPLC assay of diastereomeric composition","volume":"342","author":"Maguire J. H.","year":"1985","journal-title":"J. Chromatog."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5134-4_85"},{"key":"e_1_2_1_8_1","first-page":"231","article-title":"Phenytoin teratogenesis: correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue","volume":"203","author":"Martz F.","year":"1977","journal-title":"J. Pharmac. exp. Ther."},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)83612-9"},{"key":"e_1_2_1_10_1","first-page":"3654","article-title":"Measurement and characterization of membrane\u2010bound and soluble epoxide hydrolase activities in resting mononuclear leukocytes from human blood","volume":"44","author":"Seidegard J.","year":"1984","journal-title":"Cancer Res."},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(84)90608-7"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/6.8.1211"},{"key":"e_1_2_1_13_1","first-page":"386","article-title":"Anticonvulsant toxicity in vitro: possible role of arene oxides","volume":"217","author":"Spielberg S. P.","year":"1981","journal-title":"J. Pharmac. exp. Ther."},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198109243051302"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.156"},{"key":"e_1_2_1_16_1","first-page":"191","volume-title":"In Antiepileptic Drugs","author":"Woodbury D. M.","year":"1982"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1987.tb03212.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1987.tb03212.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T14:47:01Z","timestamp":1697813221000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1987.tb03212.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1987,10]]}},"alternative-id":["10.1111\/j.1365-2125.1987.tb03212.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1987.tb03212.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,10]]}}}